INTRODUCTION
Nutritional therapy (NT) is one of the main components in the recovery and maintenance of nutritional status in critically ill patients 1 because it provides macro-and micronutrients as energy substrates and metabolic cofactors, respectively, thus decreasing muscle and tissue degradation, increasing protein synthesis and mitochondrial function, and enhancing muscle function and mobility. 2 Nutritional therapy also reduces the risk of malnutrition, which directly impacts digestive and absorptive capacity due to the alteration of the structure of the gut barrier, contributing to an impaired systemic and intestinal immune function. 3 In this sense, early enteral nutrition (EN) can restore gut integrity, thereby reducing inflammation and increasing immunocompetence; can reduce insulin resistance, improving glucose control; and can reduce disease severity. 4, 5 Parenteral nutrition (PN) provides appropriate feeding in a timely manner and plays a key role in supporting patients with intolerance to EN. 6 Considering that the prevention of protein-energy malnutrition and other related functional disorders, such as impaired cell-mediated immunity and atrophy of the primary and secondary lymphoid organs, 7 relies on optimal nutrition support, the quantity and the quality of nutrients provided in EN and PN are important to meeting the individual needs of patients. 8 Among the most important nutrients in this regard are amino acids, including glutamine, arginine, and branchedchain amino acids (BCAAs). 9 In the mid-1970s and 1980s, the first studies that evaluated the immunomodulatory capacity of BCAAsleucine, isoleucine, and valine-appeared (see Calder for a review of the early research). An important role in maintenance of immune function was attributed to these amino acids, given that leucine is an activator of the mammalian target of rapamycin (mTOR) signaling pathway, 10 which regulates several biological processes, such as autophagy, ribosome biogenesis, and cell growth and proliferation, by monitoring the availability of nutrients, mitogenic signals, energy status, oxygen levels, and growth factors. [11] [12] [13] [14] Despite the importance of BCAAs in modulating the function of the immune system, the relevant mechanisms of action of these amino acids have still not been completely elucidated. Thus, the present review aims to synthesize available knowledge on the transport, oxidation, and biomolecular mechanisms by which BCAAs participate in inflammatory and immunological responses, as well as the role of BCAAs in NT.
TRANSPORT OF BRANCHED-CHAIN AMINO ACIDS ACROSS CELL MEMBRANES
Branched-chain amino acid transport is carried out by neutral amino acid sodium (Na þ )-independent transporters, known as solute carriers (SLC), 15 categorized into subfamilies containing different types of transporters, among them, the SLC7 family, which includes the L-type amino acid transporter (LAT) 1 (LAT1 or SLC7A5) and LAT2 (or SLC7A8) and the SLC43 family, which includes LAT3 (or SLC43A1) and LAT4 (or SLC43A2). 16 LAT1, LAT2, LAT3, and LAT4 are all able to transport BCAAs into the cells. LAT1 and LAT2 are expressed in the brain, spleen, liver, skeletal muscle, stomach, and placenta 17, 18 ; LAT3 is expressed in the liver, skeletal muscle, and pancreas 19 ; and LAT4 is expressed in the kidneys and small intestine. 20 Recent studies have also shown that LAT4 is highly present in human peripheral blood leukocytes 16 and that LAT1 is an important transporter of BCAAs in activated human T cells. 15 Although the transport is Na þ -independent, for the exchange of amino acids across the plasma membrane, both LAT1 and LAT2 depend on the type II transmembrane glycoprotein CD98 (4F2hc, SLC3A2) to which they bind, forming a high-affinity heterodimer, facilitating the translocation of LAT1 and LAT2 to the plasma membrane. 21 In contrast, LAT3 and LAT4 are facilitators of the diffusion of amino acids and do not require specific binding to surface molecules. 22 In addition, leucine transport is dependent on glutamine. First, glutamine is transported into the cells by the Na þ -dependent alanine-serine-cysteine-preferring transporter 2 (ASCT2), 23 which belongs to the SLC1 family (SLC1A5), and then is transported out of the cells by LAT1, which uses intracellular glutamine as an efflux substrate to regulate the uptake of extracellular leucine into the cells. 24 Studies show that leucine increases gene expression of ACST2 and the cationic amino acid transporter 1 (CAT1), as well as other proteins involved in BCAAs transport, such as 4F2hc and rBAT of the heteromeric amino acid transporters (HATs), emphasizing the importance of leucine in the regulation of transport of other neutral and cationic amino acids. 25 
OXIDATION OF BRANCHED-CHAIN AMINO ACIDS
Overview of the pathway of oxidation of branched-chain amino acids
The oxidation of BCAAs is self-regulated because the differing concentrations in the cytosol and in mitochondria act to maintain the equilibrium in the degradation of BCAAs for energy production.
26,27 Figure 1 shows the steps in the catabolism of BCAAs. The first step is a reversible transamination process, which results in the generation of the respective branchedchain a-keto acids (BCKAs), that is, leucine to a-ketoisocaproate (KIC), isoleucine to a-keto-b-methylvalerate (KMV), and valine to a-ketoisovalerate (KIV). 28, 29 This reaction is catalyzed by branched-chain amino acid aminotransferase (BCAT), which is subcategorized into 2 isoforms: the cytosolic (BCAT1 or BCATc), which is found in brain and in immune cells, such as activated CD4 þ T cells; and the mitochondrial (BCAT2 or BCATm), which is also seen in immune cells and in most human tissues, especially in the skeletal muscle, stomach, pancreas, and kidneys. 30, 31 Both BCAT1 and BCAT2 are absent or have low activity in the liver, restricting this tissue to oxidative decarboxylation of BCAAs. 32 The amino group (NH 3 ) originating from the transamination process catalyzed by BCAT is incorporated into a-ketoglurate to form glutamate. In turn, the amino group from glutamate can be transferred to pyruvate to generate alanine, an important process in skeletal muscle that is catalyzed by pyruvate amino transferase. 33 Addition of an amino group to glutamate generates glutamine, a reaction catalyzed by glutamine synthetase. 33, 34 The second step in BCAA catabolism is the irreversible oxidative decarboxylation of the respective BCKA, whereby the carbon skeletons of KIC, KMV, and KIV are converted to isovaleryl-CoA, 2-methylbutyryl-CoA, and isobutyryl-CoA, respectively. 30 This reaction is catalyzed by the branched-chain a-keto acid dehydrogenase (BCKD) complex, which is composed of several copies of branched-chain a-keto acid decarboxylase (E1), dihydrolipoamide acyltransferase (E2), and dihydrolipoamide dehydrogenase (E3) enzymes.
35 E1 uses a coenzyme-A reduced substrate for decarboxylation, whereas E2 uses lipoic acid as the acceptor of the decarboxylated substrate and transfers it to acetyl-CoA by reducing the lipoamide to dihydrolipoamide. E3, on the other hand, constitutes the lipoamide dehydrogenase, transferring its hydrogen to nicotinamide adenine dinucleotide (NAD) through flavin adenine dinucleotide (FAD). 35 The BCKD complex is regulated by the phosphorylation of lipoamide kinase (inhibition) and lipoamide phosphorylase (activation). 36 The third step in the catabolism of BCAAs corresponds to the adenosine triphosphate (ATP) generation process. Dehydrogenation of acyl-CoA esters and production of unsaturated a-acyl-CoA are catalyzed by isovaleryl-CoA dehydrogenase or methyl acyl-CoA branched-chain dehydrogenase. 37 As a result of this pathway, leucine is considered to be ketogenic because it forms acetyl-CoA and acetoacetate, whereas valine is glucogenic and can be converted into succinyl-CoA. Both isoleucine and valine are metabolized to succinate via methyl-malonyl-CoA. Isoleucine can also form acetoacetate and therefore can be considered a glucogenic and ketogenic amino acid. 38, 39 An alternative route of leucine metabolism, in which KIC is converted to b-hydroxy-b-methyl butyrate (HMB) in the cytosol of liver cells, involves the enzyme a-ketoisocaproate dioxygenase (KICD). 40 bHydroxy-b-methyl butyrate is related to the reduction of skeletal muscle injuries, attenuation of muscle protein degradation, increased muscle protein synthesis, the growth hormone-insulin growth factor-1 (GH-IGF-1) axis activity, and modulation of IGF-1 expression in muscle.
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Oxidation of branched-chain amino acids by the intestinal mucosa
Both BCAT and BCKD are present in the intestinal mucosa. However, whereas BCAT greatly contributes to transamination of BCAAs, BCKD is only able to decarboxylate approximately 30% of the BCKAs produced. It is suggested that this difference in metabolic activity between these 2 enzymes allows the gut to gradually use BCKAs formed throughout the digestion and Figure 1 Oxidation of branched-chain amino acids (BCAAs). In the first step, leucine, isoleucine, and valine are converted into their respective keto acids. Then, the formed keto acids are irreversibly decarboxylated. In the third step, BCAAs enter into the adenosine triphosphate generation process. Abbreviations: BCAT, branched-chain amino acid aminotransferase; BCKD, branched-chain a-keto acid dehydrogenase; HMB, b-hydroxy-b-methyl butyrate; KICD, a-ketoisocaproate dioxygenase.
absorption process as energetic substrates, avoiding the loss of free BCAAs during feeding. 35 Oxidation of branched-chain amino acids by the brain The brain also participates in oxidation of BCAAs because of the high levels of activity of BCAT and BCKD enzymes in the brain; however, the transamination rate considerably exceeds the oxidation rate. 44 The influx of BCAAs into the brain positively contributes to the control of glutamate synthesis through transamination and reamination of BCKAs, preventing high concentrations of this neurotransmitter from becoming toxic in the central nervous system (CNS). [44] [45] [46] Branched-chain amino acids, which decrease the influx of sulfonated amino acids through the blood-brain barrier, are also related to central fatigue delay and the reduction of hepatic encephalopathy symptoms. [47] [48] [49] Oxidation of branched-chain amino acids by the liver As previously mentioned, the liver shows an absence or low activity of BCAT, and as a result, unlike other amino acids, BCAAs are not primarily catabolized in this organ. 37 However, the liver has high BCKD activity, acting substantially in the decarboxylation process of BCKAs. 32 The BCKD complex activity is regulated by a phosphorylation-dephosphorylation cycle, in which the BCKD kinase is responsible for the inactivation of the complex, and the BCKD phosphatase, through a dephosphorylation process, is responsible for the reactivation of the complex. 50 BCKD kinase is inhibited by KIC, such that when tissue accumulation of KIC occurs, the BCKD complex is activated, thus promoting the oxidation of BCAAs. 50 The liver also plays a key role in the conversion of KIC to HMB: although the majority of KIC is converted into isovaleryl-CoA, approximately 5%-10% of the nondecarboxylated KIC is converted to HMB by KICD. This reaction is regulated by BCKD itself and by KICD activity. 51 Both alanine and glutamine generated through the transamination process contribute to ammonia transportation in the body, carrying this metabolite from muscle to the liver and kidneys to be metabolized and excreted, respectively, preventing its accumulation. 34, 52, 53 Considering that ammonia is toxic and its buildup is detrimental to the activity of several organ systems, such as the CNS, 54,55 the hyperammonemia state, common in liver diseases, contributes to the development of hepatic encephalopathy and the worsening of clinical conditions. 56, 57 In addition, in chronic hepatopathies, there is a reduction in the plasma concentration of BCAAs and an increase in the plasma concentration of the aromatic amino acids (AAAs) tryptophan, phenylalanine, and tyrosine. 58 This imbalance in the BCAA/AAA ratio, also called Fischer's ratio, is associated with the development of hepatic encephalopathy and progression of liver diseases. 59, 60 Oxidation of branched-chain amino acids by skeletal muscle Skeletal muscle is the major site for BCAA oxidation. The oxidation of BCAAs in skeletal muscle is regulated by BCKD, which presents 5%-8% of activity at rest and 20%-25% of activity during exercise. 61, 62 Furthermore, BCKD activity is regulated by the concentration of BCAAs and their BCKAs in muscle fibers, by depletion of muscle glycogen during and after exercise, by a decrease in pH, and by alteration in the ATP/adenosine diphosphate (ADP) ratio. 63 Skeletal muscle captures BCAAs from the bloodstream to oxidize them during prolonged exercise to generate energy. 64 This process only seems to occur when there is an exogenous supply of BCAAs (ie, it is dose-dependent) or a reduction of muscle glycogen stores. 65 Studies show that leucine supplementation decreases glycogen degradation in both the muscle and the liver because, as previously mentioned, increased serum concentrations of leucine and KIC inhibit BCKD kinase activity, enhancing BCAA oxidation and promoting a lower utilization of hepatic glycogen. 66, 67 In addition, elevated intracellular levels of leucine decrease pyruvate dehydrogenase activity, an important convergence point of the glycolytic pathway and the tricarboxylic acid (TCA) cycle, thereby promoting the conversion of pyruvate to alanine, which, in turn, acts as a precursor in hepatic gluconeogenesis. 33, 67 Besides serving as a carbon source for energy production, BCAAs also act as regulators of muscle protein turnover, inhibiting catabolism and increasing anabolism mediated by mTOR. 50, 68, 69 The maintenance of muscle protein synthesis is also influenced by the synergistic effect of insulin and leucine because this amino acid promotes an increase in the serum concentration of insulin, which, in turn, exerts a permissive effect on protein synthesis in the presence of amino acids 70, 71 and plays a key role in maintenance of glucose homeostasis, via the glucose-alanine cycle, by enhancing recycling of glucose. 68, 72 A study reported that leucine ingestion (1 mmol/kg of lean body mass) alone is not able to promote a rise in peripheral insulin concentration or a change in glucose concentration. 73 However, when administered with glucose (25 g), leucine attenuated the glucose response compared with the same amount of glucose ingested without leucine, thereby confirming the synergism between insulin and leucine. 73 
Oxidation of branched-chain amino acids by adipose tissue
In vitro and ex vivo studies show that adipose tissue is able to metabolize BCAAs, although it is not a quantitatively relevant site of BCAA catabolism. Although studies show that BCKD is the rate-determining enzyme in BCAA oxidation in muscle and liver, this enzyme does not appear to perform the same function in adipose tissue. 74 It is noteworthy that in obese humans the expression of BCAT2 and BCKD is reduced, mainly in visceral adipose tissue. 75 Adipose tissue plays an important role in the homeostatic regulation of BCAA concentrations. 76 In the mitochondria of adipocytes, the oxidized BCAAs (ie, the BCKAs) are converted into the anaplerotic TCA cycle intermediates acetyl-CoA and succinyl-CoA, which favors the generation of citrate and subsequently the process of lipogenesis. 77 In contrast with undifferentiated adipocytes, which use glucose and glutamine to generate acetyl-CoA as a lipogenic substrate, differentiated adipocytes use BCAAs, mainly leucine and isoleucine, which represent up to 30% of the lipogenic acetyl-CoA pool. As adipocyte differentiation evolves, BCAT is progressively activated. 75 
Oxidation of branched-chain amino acids by immune cells
In vitro studies have demonstrated that immune cells have high BCAT and BCKD activity levels, using isoleucine, valine and, mainly, leucine as substrates, and show increased uptake of these amino acids, mainly during the S phase of the cell cycle. 78 Moreover, in response to mitogens, the consumption of BCAAs by T cells is enhanced, with a reported increase of 270% in transport, 195% in transamination, and 122% in leucine oxidation. 79 In lymphocytes from peripheral human blood, the rate of leucine transamination is higher than the oxidation rate, suggesting that decarboxylation of KIC by BCKD plays a role in regulating the oxidation rate of leucine in these cells. 80 In addition, in vitro studies show that leucine appears to be a key regulator of its own oxidation and also the oxidation of other amino acids because high levels of leucine decrease the extracellular concentrations of valine, isoleucine, and their a-keto acids. 81 On the other hand, a low concentration of isoleucine, valine, and glutamine may exert an inhibitory effect on the transamination and oxidation of leucine. 80 During their activation, T cells undergo metabolic reprogramming, increasing the demand for amino acids to sustain the high rate of protein synthesis. These cells decrease oxidative decarboxylation of pyruvate, and the formation of lactate regenerates the NAD þ necessary to continue generating energy. Additionally, BCAA transamination triggered by BCAT1 increases in activated T cells.
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In liver-associated lymphocytes-large granular and agranular lymphocytes-BCAAs, especially valine, increase cell proliferation by stimulating lymphopoiesis, and they also increase natural killer (NK) and lymphokine-activated killer activity. 83 Hematopoietic stem cells (HSCs) are especially sensitive to amino-acid deprivation and, in order to maintain their integrity, rely on a complex system promoted by nonhematopoietic cells in bone marrow. It has been found that valine and leucine deprivation during the growth of human HSCs is detrimental and results in impairment of the number of white and red blood cells.
84,85

Oxidation of branched-chain amino acids in other tissues
The distribution of BCAT was also determined in other tissues by enzymatic assays and Western blotting analysis. The activity of BCAT2 is high in gastric cells, the pancreas, and salivary glands, 35 whereas BCAT1 has its greatest activity in the ovaries and placenta. 86 BCKD also has high activity in gastric cells and kidneys. 32 
INTRACELLULAR SIGNALING MECHANISMS OF BRANCHED-CHAIN AMINO ACIDS: THE MAMMALIAN TARGET OF RAPAMYCIN PATHWAY
Belonging to the phosphatidylinositol 3-kinase-related kinases (PIKKs) superfamily, mTOR is a conserved protein kinase divided into 2 distinct complexes, mTORC1 and mTORC2. mTORC1 contains mTOR, the regulatory protein associated with mTOR (Raptor), the Gprotein b-subunit-like protein (GbL or mammalian lethal with Sec13 protein 8-mLST8), the proline-rich Akt substrate of 40 kDa (PRAS40), and the DEP domain-containing mTOR-interacting protein (Deptor).
87 mTORC2 contains mTOR, Deptor, GbL, the rapamycin insensitive companion of mTOR (Rictor), mammalian stress-activated protein kinase interacting protein 1 (mSIN1), and the protein observed with Rictor (Protor). 88 
Upstream regulation of mTORC1
The major sensor involved in mTORC1 activity is the tuberous sclerosis complex (TSC), which is a heterodimer of TSC1 (or hamartin) and TSC2 (or tuberin). 89 When stimulated by growth factors, mTORC1 is upstream-regulated by the phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) pathway or by extracellular-signal-regulated kinase 1 and 2 (ERK1/ ERK2), which increase the phosphorylation of TSC2, leading to the inactivation of the TSC1-TSC2 complex with subsequent activation of mTORC1. 90 The TSC1 and TSC2 proteins form a suppressor complex that functions as a GTPase-activating protein (GAP) for the Ras homolog enriched in brain (Rheb), a small GTPase that, when bound to guanosine triphosphate (GTP), directly interacts with mTORC1. [91] [92] [93] [94] The cell energy status is regulated by mTOR activity by a different pathway mediated by the AMP-activated protein kinase (AMPK). AMPK is activated in response to a low ATP/ ADP ratio, phosphorylating the TSC2, thus increasing the GAP activity of this complex toward Rheb, leading to reduced mTORC1 activation. Moreover, in response to energy depletion, AMPK can directly phosphorylate Raptor, likewise reducing mTORC1 activity. 95 The increased intracellular concentration of amino acids, including leucine, promotes the activation of mTORC1 as well ( Figure 2 ). The activation of mTORC1 promoted by leucine is mediated by the Rag guanine triphosphatases (GTPases), which function as heterodimers with active complexes of GTP-bound RagA or B complexed with GDP-bound RagC or D. 96 The GTP loading of RagA/B proteins binds to Raptor and promotes the translocation of mTORC1 to the lysosome, where the GTP-bound Rheb stimulates the kinase activity of mTORC1. 97 The Rag GTPase complex is also dependent on the interaction with the Ragulator complex (LAMTOR1, 2, 3, 4, and 5) through the C-terminal domains of RagA/B and RagC/D, which serve as a guanine nucleotide exchange factor for RagA and RagB, promoting their GTP binding in exchange for GDP and recruiting the Rag GTPases to lysosomes. 98, 99 The absence of amino acids shifts Rag into an inactive form of GDP-bound RagA/B and GTP-bound RagC/D, inactivating mTORC1. 97 The negative regulation of the Rag GTPases is stimulated by 2 GAP complexes: GATOR1, which acts on RagA and RagB, and Folliculin (FLCN)-folliculin interacting protein 2 (FNIP2), which acts on RagC and RagD.
100 GATOR1 is negatively regulated by the GATOR2 complex, which consists of interacting proteins such as Sestrin2, a leucine sensor upstream of mTORC1. 101 Studies show that leucine binds to Sestrin2, disrupting the Sestrin2-GATOR2 interaction, thus activating mTORC1. [102] [103] [104] As with Sestrin2, leucyl-tRNA synthetase (LRS) also mediates leucine signaling in the mTORC1 pathway. 105 In the presence of amino acids, LRS is translocated to the lysosome, where, acting as a GAP, it facilitates the GTP hydrolysis of RagC/D, resulting in the formation of GDP-RagC/D and the activation of mTORC1. 105, 106 In this sense, whereas Sestrin 2 is a negative regulator of mTORC1, LRS is a positive regulator of mTORC1. 107 
Upstream regulation of mTORC2
So far, the mechanisms involved in mTORC2 activation are not well described. However, it has recently been shown that phosphatidylinositol (3, 4, 5)-tris-phosphate (PIP 3 ), generated downstream of PI3K, promotes mTORC2 activity through mSin1 binding, a component present exclusively in mTORC2, essentially for the activation of this complex. 108 Stimulated by amino acids, mTORC2 plays a role in Akt (Serine473), protein kinase C (PKC) a, and serum and glucocorticoid-inducible kinase (SGK) activation ( Figure 3) . 109, 110 PKCa regulates multiple cellular functions, such as adhesion, secretion, proliferation, differentiation, and apoptosis, 111 whereas SGK alters the activity of several enzymes, such as inducible nitric oxide synthase (iNOS), and regulates cell survival and proliferation, muscle mass maintenance, and the organization of the cytoskeleton. 112 mTORC2 plays a role in the organization of the actin cytoskeleton, as well as in the regulation of PKC. 110 It has also been shown that Rictor plays an essential role in T-cell amino-acid sensing because,e in the absence of this component, CD4
þ T cells proliferate normally, even in limiting leucine. This finding suggests that Rictor controls an amino acid-sensitive checkpoint that permits T cells to determine whether the microenvironment contains sufficient resources for cell generation.
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Protein synthesis: S6K/eIF pathway
The activation of mTORC1 by both insulin and amino acids leads to the phosphorylation of the ribosomal S6 kinase (S6K) and the eukaryotic initiation factor (eIF) 4E-binding protein 1 (4E-BP1), which promotes protein synthesis and cell growth. 114 4E-BP1 is an inhibitory phosphoprotein that, when hypophosphorylated, is bound to eIF4E and hinders the recruitment and assembly of the eIF4F complex. 115 The eIF4F complex consists of 4 major components: eIF4E, a protein that binds to the 5 0 -cap structure of the messenger RNA (mRNA); eIF4A, a canonical DEAD-box helicase; eIF4G, a scaffold protein that binds eIF4E, eIF4A, and the mRNA transcript itself; and poly(A)-binding protein (PABP), which binds to the 3 0 poly(A) tail of eukaryotic mRNA, initiating the translation process. 116, 117 Phosphorylation of the inhibitory 4E-BP1 protein enhances the formation of the elF4F complex, promoting translation initiation. Additionally, activated S6K phosphorylates the eIF4B, a regulator of eIF4A, increasing the affinity of eIF4A for ATP and its helicase activity, thus providing an extra stimulus for the initiation of translation. [117] [118] [119] There are 2 S6K proteins, S6K1 and S6K2, both belonging to the cAMP-dependent, cGMP-dependent, and protein kinase C kinase family. 120 Both S6K1 and S6K2 have important regulatory domains: the acidic Nterminus that contains the TOS (TOR signaling) motif; the kinase domain that contains the T-loop; a linker region that contains the TM and HM sites; and a basic Cterminus containing an autoinhibitory pseudosubstrate domain.
121 S6K1 phosphorylation (Thr389 residue) on multiple C-terminal sites facilitates mTORC1-mediated phosphorylation of the HM site (Thr389) in the linker domain and phosphoinoisitide-dependent kinase 1 (PDK1)-mediated phosphorylation of the T-loop site (Thr229). 122, 123 Leucine is the most potent amino acid known to activate the mTOR/S6K pathway. 124 Studies show that acute provision of leucine enhances mTOR and S6K activation in the heart of rats and in human myotubes independently of insulin stimulation. 125, 126 It is also been reported that the intake of an essential amino-acids mixture together with leucine may potentiate leucinemediated mTOR signaling in skeletal muscle due to increased S6K phosphorylation. 127 KIC can also stimulate 4E-BP1 phosphorylation. 128 
Insulin cascade: IRS-1 pathway
The insulin receptor is a transmembrane tyrosine kinase that coordinates intracellular signaling cascades promoting the biological action of insulin. 129 Insulin binding to its receptor promotes the phosphorylation of tyrosine residues of the cytosolic insulin receptor substrates (IRSs) 1 and 2. This leads to the activation of the PI3K/Akt pathway, which is responsible for the majority of the metabolic actions of insulin, and to the activation of the Ras/mitogen-activated protein kinase (MAPK) pathway, which regulates the expression of Figure 3 Upstream regulation of mTORC2 by branched-chain amino acids (BCAAs). mTORC2 is activated by PIP 3 acting on mSIN1, leading to the activation of PKCa, SGK, and Akt (Ser473). Abbreviations: BCAAs, branched-chain amino acids; Deptor, DEP domain-containing mTOR-interacting protein; GbL, G-protein b-subunit-like protein; mSIN1, mammalian stress-activated protein kinase interacting protein 1; mTORC2, mammalian target of rapamycin complex 2; Protor, protein observed with Rictor; Rictor, rapamycin insensitive companion of mTOR.
many genes and links with the PI3K pathway to control cell growth and differentiation. 130 Akt phosphorylates and inhibits the Rab-GTPaseactivating protein, triggering the activation of Rab small GTPases involved in the cytoskeletal reorganization, which culminates in the translocation of the glucose transporter GLUT4 to the plasma membrane. 130 Besides Akt, the atypical protein kinase C isoforms f and k (PKCf/k) also promote GLUT4 translocation, thus controlling glucose transport into the cell. 131 At the same time, Akt also phosphorylates and inhibits TSC2, leading to activation of the mTOR pathway, with subsequent activation of S6K and eIF4E. 130 Both hyperactive mTOR and S6K1 negatively regulate Akt by inducing IRS-1 serine phosphorylation, disrupting the interaction between insulin and its receptor, leading to degradation. 69 In this context, when high levels of BCAAs persistently activate mTORC1, insulin resistance is induced through a negative feedback loop of IRS-1. 69 In addition, mTORC2 promotes the negative feedback of IRS-1 and prevents its inactive form from accumulating in the cytosol through the stabilization of the substrate-targeting subunit of the CUL7 E3 ligase complex (Fbw8), which, in turn, mediates the ubiquitination and degradation of IRS-1. 132 However, it is poorly understood whether physiological levels of BCAAs may induce mTOR activation and subsequent IRS-1 and IRS-2 serine phosphorylation. Some studies suggest that impaired insulin sensitivity mediated by S6K is only affected by transient high-protein diets (<6 wk) because, in longer interventions (6-18 wk), highprotein diets did not affect S6K1 expression. 69 Despite the evidence that supplementation with BCAAs or intake of a BCAA-rich diet improves metabolic health, 133 levels of BCAAs tend to be increased in insulin-resistant obesity and type 2 diabetes mellitus (T2DM). 134 Recent studies suggest that these effects may depend on ethnicity. 135 Epidemiological studies have suggested that elevated levels of plasma BCAAs are associated with insulin resistance, substantial secretory pressure on the pancreatic b cells, and onset of T2DM in European whites, Chinese, and South Asians, highlighting the decreased expression of enzymes that metabolize BCAAs and an increase in muscle protein degradation as the possible mechanisms involved. 135 Other recent evidence has suggested an inverse correlation between plasma BCAAs and insulin clearance and a contribution of BCAAs to the development of obesityassociated insulin resistance in overweight individuals who submit to a high-saturated-fat diet. 135, 136 It is well known that diabetes can substantially increase the risk of developing certain cancers. 137, 138 Because oncological patients have a substantial reduction in muscle mass (cachexia), 139 supplementation with BCAAs has been shown to be an important strategy for inhibiting protein catabolism, stimulating protein synthesis, and promoting muscle repair. 140 However, considering previous reports that elevated plasma levels of BCAAs are related to the development of insulin resistance and diabetes, this effect should be considered prior to any therapeutic strategies involving administration of BCAAs. 141 Under hyperinsulinemic conditions, BCAAs act as a suppressor of insulininduced overactivation of PI3K/Akt by both inducing a negative feedback loop though mTORC1/S6K1 activation and suppressing mTORC2 kinase activity toward Akt, exhibiting growth inhibitory effects by inducing apoptosis. 142 
Inflammation: nuclear transcription factor kappa B pathway
The nuclear transcription factor kappa B (NF-jB) comprises 5 members in mammals: c-REL, RELB, NF-jB1 (or p105), NF-jB2 (or p100), and RELA (or p65). 143 RELA is responsible for most NF-jB transcriptional activity due to the presence of a strong transcriptional activation domain. 144 The NF-jB pathway is activated by several stimuli, such as tumor necrosis factor a (TNFa), interleukin 1 (IL-1), lipopolysaccharide (LPS), heat shock proteins (Hsp), and T-cell activators. 145 These activators induce the activation of the I-kappaB-kinase (IKK) enzyme complex (IKKa, IKKb, and IKKc), which phosphorylates the inhibitory IjBa proteins, inducing their ubiquination and proteasome-dependent degradation. This allows the translocation of NF-jB to the nucleus. 146 NF-jB is responsible for the upregulated synthesis of immune-related cytotoxic factors such as iNOS, cyclooxygenase 2 (COX-2), and proinflammatory cytokines, which contribute to the eradication of infectious agents. 147, 148 Dysregulated and prolonged activation of NF-jB can trigger tissue damage, multiple organ failure, and even death. Therefore, the inhibition of this factor may be a key target in patients with sepsis. NFjB has also been recognized as an important target in the treatment of several types of cancer because its inhibition results in apoptosis of cancer cells and in reduced levels of vascular endothelial growth factor (VEGF) produced in leukemia, glioma, and rheumatoid arthritis. 56, 142, 149 The mTOR signaling pathway plays a key role in the inflammatory response mediated by NFjB. 150 It has been demonstrated that IKKb phosphorylates and suppresses TSC1, thus activating the mTOR pathway, which enhances angiogenesis, resulting in tumor development, and is associated with VEGF production in multiple tumor types. 151 Moreover, it has been reported that mTOR reciprocally activates IKK and NFjB when IKKa is induced to interact with mTORC1. 152 Some studies show that TNF-a may also stimulate Akt activity from interaction with IKKb, leading to activation of NF-jB, which contributes to cell proliferation, tumor growth, and angiogenesis. 153 TNF-a binding to its receptor TNFR1 leads to the recruitment of the TNFR1-associated death domain (TRADD) protein, followed by the recruitment of the FAS-associated death domain (FADD) protein, TNF receptor-associated factor 2 (TRAF2), and the receptor-interacting protein 1 (RIP1) kinase. 154, 155 The TRAF2-RIP1 association promotes the activation of IKKb. 156 Lipopolysaccharide also stimulates the mTOR pathway. Lipopolysaccharide induces the NF-jB pathway through binding to toll-like receptors (TLRs), which, in turn, activate mTOR via the PI3K/Akt pathway. 157, 158 Activated mTOR associates with the adapter protein MyD88, allowing the activation of the interferon regulatory factor (IRF) 5 and IRF-7, key transcription factors involved in regulation of the expression of genes encoding proinflammatory cytokines and type I interferons (IFNs). 157 It has also been demonstrated that activation of the mTOR/IjB-a/NF-jB pathway increases the expression of iNOS and COX-2, thus promoting a vasodilatory and proinflammatory effect that contributes to LPS-induced hypotension and inflammation. 148 Considering that some autoimmune diseases are driven by type I IFN and LPS-induced endotoxemia involves proinflammatory cytokines, the short-term inactivation of mTOR may be an interesting strategy to control the progression and symptoms of certain pathological conditions. 148, 157 Paradoxically, the inflammatory insult produced by LPS may decrease mTOR, 4E-BP1, and eIF4G phosphorylation, leading to impaired protein synthesis, thus decreasing lean body mass. 159 Nevertheless, the mechanism involved in this response is not well understood because the activation of Akt is not affected by LPS. 159 Concomitantly, LPS may impair the anabolic response to amino acids, notably mTOR-dependent muscle protein synthesis activated by leucine. 160 Animal studies show that even a high dose of leucine is not able to increase muscle protein synthesis in sepsis, probably because of a sepsis-induced leucine resistance mechanism, which could explain, at least in part, the findings of muscle wasting in septic patients that was not reversed by supplementation with BCAAs. 159 A plausible hypothesis to explain this resistance to leucine may involve the depletion of intramuscular glutamine due to its release by skeletal muscle during sepsis, impairing the transport of leucine into the muscle or the ability of the muscle to "detect" leucine because, as previously mentioned, transport of leucine is highly dependent on the intracellular concentration of glutamine. 161, 162 Aging: SIRT1 pathway Sirtuin 1 (SIRT1) is a NAD þ -dependent deacetylase that regulates calorie restriction-mediated longevity and is associated with the insulin signaling pathway, regulating various cellular processes, including aging. 163, 164 As a member of the sirtuin family, this deacetylase is also associated with increased mitochondrial biogenesis, maintenance of the cellular energetic state, increased activity of antioxidant defense systems, and decreased synthesis of reactive oxygen species. 165, 166 Both SIRT1 and mTOR have been related to ageassociated diseases such as T2DM, obesity, cardiovascular disease, cancer, and neurodegenerative diseases 165 : activation of SIRT1 exerts a therapeutic effect in some of these diseases, whereas inhibition of mTOR confers the protective effect. 167 It has been proposed that SIRT1 activity is primarily regulated by telomerase, and there is evidence that SIRT1, which is a deacetylase enzyme, acts as a nutrient-responsive growth suppressor by regulating mTOR signaling. 168, 169 The interconnection of SIRT1 and mTOR is related to the promotion of stress-sensing prosurvival signals. This seems to not directly involve mTOR, but rather the interaction of SIRT1 with TSC1-TSC2 exerting an inhibitory effect on mTOR, similar to that performed by TSC2. 167 Autophagy is an important mechanism of control in response to stress and aging; autophagy is negatively regulated by mTOR, whereas SIRT1 activates autophagy by deacetylating several essential components of the autophagy machinery. [170] [171] [172] Studies have shown that inactivation of SIRT1 impairs starvation-induced autophagy, resulting in the activation of NF-jB and subsequent inflammation. 173 In contrast, SIRT1 deficiency promoted mTOR signaling that could not be reversed even under cellular stress caused by leucine starvation and other stress-inducible stimuli. 167 Many studies have found associations between BCAAs or leucine supplementation and attenuation of high-fat-diet-induced mitochondrial dysfunction, insulin resistance, and obesity 165 or muscular metabolic changes and mitochondrial biogenesis. 174 However, reports from these studies do not mention the role of mTOR in these processes, instead linking these events only to the increased expression of SIRT1 mediated by the AMPK signaling pathway, leading to reduced acetylation of the peroxisome proliferator-activated receptorgamma coactivator 1a (PGC1a) and the forkhead box protein O1 (FoxO1). 175 Notwithstanding this, it is hypothesized that the enhanced mitochondrial biogenesis promoted by BCAAs could be mediated by a positive feedback mechanism between the nitric oxide-generating system and mTOR because nitric oxide regulates mTOR activity and its downstream proteins. 166 Lipid metabolism: proliferator-activated receptor c pathway Another example of the regulatory potential of mTOR is found in nuclear receptor signaling involving peroxisome proliferator-activated receptor c (PPARc), considered to be the major regulator of adipocyte differentiation and glucose and lipid metabolism in mature adipocytes. 176 In adipose tissue, mTOR activation is related to an increase in fat mass in obesity, whereas inhibition of mTOR is associated with a reduction in fat mass in situations of caloric restriction and fasting. 177 mTOR is known to modulate the activity of PPARc by translating signals of nutrient availability. 178 Activation of mTORC1 induces the phosphorylation of 4EBP-1, releasing eIF4E, which is required to increase the translation of CCAAT-enhancer binding proteins (C/EBP) a and d, seen in adipose tissue. 179 This transcription factor is necessary for establishing the adipogenic cascade because C/EBP-d increases the amount of C/EPB-a and PPARc. 180 When sufficient levels of PPARc are produced, this transcription factor promotes adipogenesis and lipid synthesis through increased expression of lipogenic genes. 181 In adipocytes, mTOR is responsible for the control of protein synthesis, the morphogenesis of adipose tissue, and the synthesis and secretion of leptin. 182 Studies show that leucine has a positive effect on adipocyte differentiation by regulating PPARc and C/EBP-a via the mTOR pathway. 183 However, the results from manipulation of dietary leucine are inconsistent, 184 inasmuch as a study showed that an increase in dietary leucine has no effect on lipid metabolism, 185 whereas leucine deprivation reduced body weight and abdominal adipose mass and improved metabolic health. [186] [187] [188] More studies are needed to further investigate the role of BCAAs on lipid metabolism. The mechanisms described above are illustrated in Figure 4 .
BRANCHED-CHAIN AMINO ACIDS IN NUTRITIONAL THERAPY AND IMMUNOMODULATION
Research into the association between BCAAs and immunomodulation began in the 1970s and 1980s, when researchers evaluated critically ill patients receiving total parenteral nutrition (TPN) and observed that an increase in the total amount of BCAAs in the formula resulted in elevation of lymphocyte counts in blood and reduced mortality, mainly in the postoperative period and in cases of sepsis (Table 1) 190, 191, 193, 194, 198, [202] [203] [204] [206] [207] [208] [209] [210] 214 Furthermore, when plasma amino-acid concentrations were compared, surviving patients were found to have higher concentrations of BCAAs and lower concentrations of aromatic and sulfur amino acids than those who did not survive sepsis, indicating a preserved liver function and better maintenance of energy metabolism. 189 Considering that hepatic failure is a common cause of death in septic patients, this result demonstrates the beneficial effect of BCAA supplementation on patient survival. 192 Bower et al 193 made both quantitative and qualitative analyses of TPN for septic patients. They used 3 formulas with different proportions of BCAAs. The standard control formula contained 25% BCAAs (660 mg/mL of leucine, 560 mg/mL of valine, and 510 mg/mL of isoleucine), whereas the other 2 formulas contained 45% BCAAs, 1 with a predominance of leucine (1576 mg/mL leucine, 789 mg/mL valine, and 789 mg/mL isoleucine) and another with a predominance of valine (263 mg/mL leucine, 1838 mg/mL valine, and 1050 mg/mL isoleucine). In the first phase of the study, the valine-rich solution was insufficient to maintain a plasma concentration of amino acids and protein turnover; however, the leucine-rich solution proved to be more effective in this context. It is possible that the positive result obtained with the administration of the leucine-rich solution was mediated by the secretagogue effect of leucine on insulin, as mentioned earlier. Nevertheless, nitrogen balance was marginally improved with both solutions, although the cumulative nitrogen balance was not altered (Table 1) .
Vente et al 194 observed that a BCCA-enriched solution (50.2% of total amino-acid content) compared with a standard TPN solution (BCAAs at 15.6% of total amino-acid content) was ineffective in improving nitrogen metabolism in septic and traumatized patients. Considering that the control group was not deprived of BCAAs, the increase in BCAAs did not confer additional benefits on the proliferation of lymphocytes. Even so, the presence of BCAAs is indispensable for cellular growth and proliferation, as mentioned in a report by Chuang et al, 195 who found that lymphocyte proliferation was dependent on 15 amino acids, among them BCAAs, and the absence of any of these amino acids directly impacted on cell proliferation (Table 1) .
In addition to directly impacting the functions of immune cells, BCAAs also affect liver function. Branched-chain amino acids may be used as energy sources, thus improving nitrogen balance. They also have a beneficial effect on the anorexia associated with hepatocellular failure because they promote muscle protein balance. 196 However, such an effect on lean body mass is dependent on adequate protein intake and quality. 197 Supplementation with BCAAs, especially when associated with a high-fiber, high-protein diet, is considered a safe intervention in patients with cirrhosis, with the BCAAs contributing to the increase of muscle mass, not raising the levels of ammonia or glucose, and not being associated with the development of hepatic encephalopathy (Table 1) . 198 The European Society for Clinical Nutrition and Metabolism recommends a protein intake of 1.2-1.5 g/kg of body weight/day for patients receiving EN or PN, as well as oral supplementation with BCAAs, to improve clinical outcome in advanced cirrhosis. 199 The addition of 35%-45% BCAAs and the reduction of aromatic amino acids (phenylalanine, tyrosine, and tryptophan) and sulfur amino acids in total PN for cirrhotic patients with hepatic encephalopathy are also recommended. 200 Furthermore, supplementation with BCAAs may reduce ascites symptoms in these patients as a result of increased total serum protein and serum albumin levels. 201 A study conducted by Nakamura et al 202 evaluated the effect of supplementation with 12 g/day of BCAAs (2.8 g of isoleucine, 5.7 g of leucine, and 3.4 g of valine per day) on neutrophil phagocytic function, NK cell activity, plasma albumin concentrations, and Fisher's ratio in patients with hepatic cirrhosis. After 3 months of supplementation, Fisher's ratio was increased; however, there was no statistical difference in plasma albumin concentrations. The authors also observed a substantial improvement in neutrophil phagocytic function and lymphocyte NK cell activity, concluding that BCAAs supplementation could reduce the risk of bacterial and viral infections in patients with decompensated cirrhosis (Table 1) .
Because NK cells also play an important role in tumor defense, BCAA supplementation for patients with cirrhosis could reduce the risk of development of various liver cancers. 202 Several studies indicate that supplementation with BCAAs is associated with a lower incidence of hepatocellular carcinoma (HCC) in patients with cirrhosis and may improve nutritional status and quality of life (Table 1) . [203] [204] [205] [206] [207] [208] Moreover, in patients undergoing therapeutic interventions for treatment of HCC, supplementation with BCAAs prevents a Figure 4 Intracellular mechanisms of modulation of the mTOR pathway by branched-chain amino acids (BCAAs). mTOR activation is associated with several pathways, including S6K, IRS-1, NF-jB, SIRT-1, and PPARc. TSC1 and TSC2 are the major sensors involved in mTORC1 activity and regulation. Abbreviations: Akt, protein kinase B; BCAA, branched-chain amino acids; eIF4F, eukaryotic initiation factor 4F complex; C/EPB, CCAAT-enhancer-binding proteins; FADD, FAS-associated death domain; Fbw8, substrate-targeting subunit of the CUL7 E3 ligase complex; GLN, glutamine; IjBa, I-kappaB-kinase-a; IKK, I-kappaB-kinase enzymatic complex; IR, insulin receptor, IRS-1, insulin receptor substrate 1; LAT, L-type amino acid transporter; LPS, lipopolysaccharide; mTORC1, mammalian target of rapamycin complex 1; mTORC2, mammalian target of rapamycin complex 2; MyD88, cytoplasmatic adapter protein; NF-jB, nuclear transcription factor kappa-B; PI3K, phosphatidylinositol 3-kinase; PPARc, peroxisome proliferator-activated receptor c; Rheb, Ras homolog enriched in brain; RIP1, receptor-interacting protein 1; S6K, ribosomal S6 kinase; SIRT1, sirtuin 1; TAK1, TGF-b-activated kinase 1; TLR4, toll-like receptor 4; TNF-a, tumor necrosis factor a; TNFR, tumor necrosis factor receptor; TRADD, associated death domain; TRAF2, TNF receptor-associated factor 2; TRAF6, TNF receptor-associated factor 6; TSC, tuberous sclerosis complex; 4E-BP1, eukaryotic initiation factor 4E-binding protein 1. decrease in serum albumin level and reduces postoperative complications (Table 1) . 209 In addition to the beneficial effects on HCC, supplementation with BCAAs is related to improvement of the inflammatory state and the nutritional status of patients with gastrointestinal cancer. Sun et al 210 investigated the potential benefits of parenteral administration of a solution enriched with 30% BCAAs in undernourished patients with gastrointestinal cancer undergoing surgery. Decreased leukocyte count and plasma C-reactive protein (CRP), alkaline phosphatase, and gamma-glutamyl transferase (c-GT) levels were observed. The enriched solution also maintained stable albumin and prealbumin concentrations and a positive nitrogen balance. In this study, the authors observed a decrease in the incidence of postoperative comorbidities (Table 1) .
Cancer patients often present in an advanced state of malnutrition, leading to intense metabolic stress and catabolic states characterized by increased energy consumption, negative nitrogen balance, increased glutamine utilization, and altered amino acid metabolism. In an attempt to compensate for the increase in energy expenditure and glutamine consumption, there is an increase in BCAA oxidation in skeletal muscle. Studies show that glutamine supplementation improves nitrogen balance and recovery from infection in various clinical conditions, such as burns, radiation injury, severe surgical stress, sepsis, and cancer. 211 The increased availability of glutamine also promotes an increase in glutamate, which is a component of glutathione, the main nonenzymatic intracellular antioxidant. 212 In this sense, the immunomodulatory and antioxidant role of BCAAs, whether direct or indirect, may be of great importance for the prevention and treatment of other conditions involving inflammatory and oxidative states. 213 On the other hand, the effect of supplementation with BCAAs on nutritional status in well-nourished individuals is poorly elucidated. Verhoeven et al 214 found no changes on skeletal muscle mass and strength, as well as no improvements in indexes of whole-body insulin sensitivity (oral glucose insulin sensitivity index and the homeostasis model assessment of insulin resistance), blood glycated hemoglobin content, or the plasma lipid profile, in healthy elderly men after supplementation with 7.5 g of leucine per day. However, it is noteworthy that in this study, there was a decline of 18%-25% of basal plasma valine concentration in the supplemented group, suggesting an amino-acid imbalance (Table 1) . Thus, further studies are needed to understand the effects of supplementation with BCAAs on nutritional status in well-nourished patients.
CONCLUSION
Branched-chain amino-acid supplementation has been widely used over the years, especially in clinical conditions of hepatopathy, trauma, cancer, and sepsis, in which there is impairment of immune function, loss of lean mass, increased inflammation, and oxidative stress. In this sense, BCAAs can contribute to the reversal of these symptoms, the recovery of homeostasis, and the prevention of patient's worsening, thus improving clinical outcomes and, more substantially, reducing mortality. Nevertheless, the literature lacks studies that elucidate in a clear and integrated way the roles and mechanisms of action of BCAAs because, in certain situations, the results found in clinical practice do not corroborate the biomolecular mechanisms of BCAA action and vice versa. The major research areas that require attention that are identified by this literature review are as follows:
1. Better elucidation of the proinflammatory and adipogenic roles promoted by mTOR in association with the NF-jB and PPARc pathways, respectively. 2. Better elucidation of the synergistic action of leucine and insulin, especially in at-risk groups, as well as better understanding of the role of the overactivation of mTOR and S6K1 that results in insulin resistance. 3. Whether the beneficial effects of BCAA supplementation on protein synthesis outweigh any possible harmful effects on inflammation and adipogenesis. Abbreviations: ALT, alanine aminotransferase; BCAAs, branched-chain amino acids; CRP, C-reactive protein; HCC, hepatocellular carcinoma; NK, natural killer; TPN, total parenteral nutrition; c-GT, gamma-glutamyl transferase.
4. Finally, considering that the activation of BCAAstimulated mTOR is mainly related to proinflammatory effects, better understanding is needed of the mechanisms underlying the beneficial effects of BCAAs in clinical practice, especially in situations of sepsis and inflammation.
